urapidil kalceks süste-/infusioonilahus
kalceks as - urapidiil - süste-/infusioonilahus - 50mg 5tk
urapidil kalceks süste-/infusioonilahus
kalceks as - urapidiil - süste-/infusioonilahus - 25mg 5tk
tachyben infusioonilahuse kontsentraat
ever neuro pharma gmbh - urapidiil - infusioonilahuse kontsentraat - 5mg 1ml 20ml 5tk
tachyben süstelahus
ever neuro pharma gmbh - urapidiil - süstelahus - 5mg 1ml 10ml 5tk
tachyben süstelahus
ever neuro pharma gmbh - urapidiil - süstelahus - 5mg 1ml 5ml 5tk
virophta silmatilgad, lahuse pulber ja lahusti
tubilux pharma s.p.a. - trifluridiin - silmatilgad, lahuse pulber ja lahusti - 1% 5ml 1tk
viroptic silmatilgad, lahus
dsm pharmaceuticals inc. - trifluridiin - silmatilgad, lahus - 1% 7.5ml 1tk
virophta silmatilgad, lahuse pulber ja lahusti
allergan pharmaceuticals ireland - trifluridiin - silmatilgad, lahuse pulber ja lahusti - 1% 5ml 1tk
lonsurf
les laboratoires servier - trifluridine, tipiracil vesinikkloriid - kolorektaalne kasvaja - antineoplastilised ained - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukeemia, müeloid - antineoplastilised ained - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.